PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of jcbfmJournal of Cerebral Blood Flow & Metabolism
 
J Cereb Blood Flow Metab. 2010 January; 30(1): 70–78.
Published online 2009 September 2. doi:  10.1038/jcbfm.2009.185
PMCID: PMC2801771
NIHMSID: NIHMS139161

Fenofibrate improves cerebral blood flow after middle cerebral artery occlusion in mice

Abstract

Fibrates, one group of peroxisome proliferator-activated receptor (PPAR) activators, are lipid lowering drugs. Fibrates have been shown to attenuate brain tissue injury after focal cerebral ischemia. In this study, we investigated the impact of fenofibrate on cerebral blood flow (CBF) in male wild type and PPARα-null mice. Animals were treated for 7 days with fenofibrate and subjected to 2 h of filamentous middle cerebral artery occlusion and reperfusion under isoflurane anesthesia. Cortical surface CBF was measured by laser speckle imaging. Regional CBF (rCBF) in nonischemic animals was measured by 14C-iodoantipyrine autoradiography. Fenofibrate did not affect rCBF and mean arterial blood pressure in nonischemic animals. In ischemic animals, laser speckle imaging showed delayed expansions of ischemic area, which was attenuated by fenofibrate. Fenofibrate also enhanced CBF recovery after reperfusion. However, such effects of fenofibrate on CBF in the ischemic brain were not observed in PPARα-null mice. These findings show that fenofibrate improves CBF in the ischemic hemisphere. Moreover, fenofibrate requires PPARα expression for the cerebrovascular protective effects in the ischemic brain.

Keywords: autoradiography, cerebral ischemia, eNOS, fibrate, nuclear receptors, neuroprotection

Introduction

Fibrates are lipid lowering drugs and they are used in patients with hypercholesterolemia and hypertriglyceridemia. Fibrates activate peroxisome proliferator-activated receptors (PPARs) with a higher affinity for PPARα than that for PPARγ and PPARδ (Gibson, 1993; Dreyer et al, 1993; Green and Wahli, 1994). PPARs are ligand-activated transcription factors belonging to the nuclear receptor family. They are important in lipid and glucose metabolism (Chinetti et al, 2000). In addition, PPARs have been shown to support multiple cellular functions, such as antiinflammatory and antioxidative effects (Staels et al, 1998; Escher and Wahli, 2000; Von Knethen and Brune, 2001). Pleiotropic actions of fibrates, such as antiinflammatory action (Cunard et al, 2002; Staels et al, 1998) and antioxidative action (Escher and Wahli, 2000; Von Knethen and Brune, 2001), contribute to their protective effects against ischemia and reperfusion in peripheral organs including kidney, heart, and intestine (Sivarajah et al, 2002; Wayman et al, 2002; Yue et al, 2003; Cuzzocrea et al, 2004). Little is known about the effects of fibrates on circulation in the ischemic tissues.

Fibrates have been shown to be beneficial against inflammation-associated central nervous system injury (for review, see Bordet et al, 2006). For example, Lovett-Racke et al (2004) showed that fenofibrate and gemfibrozil improved clinical signs of experimental autoimmune encephalomyelitis in mice. Deplanque et al (2003) showed reduced expression levels of proinflammatory molecules in the ischemic brain. Moreover, fenofibrate also attenuated brain infarct size in mice subjected to focal cerebral ischemia (Inoue et al, 2003; Deplanque et al, 2003). Wy-14643, a PPARα-specific ligand, had similar effects against permanent focal cerebral ischemia (Inoue et al, 2003). The attenuation in inflammation by fenofibrate could reduce infarct size. Conversely, the attenuated inflammation could be the consequence of brain protection by fenofibrate through non-antiinflammatory actions.

Cerebral blood flow (CBF), particularly in the penumbra, is a critical determinant to outcome after ischemic stroke. Although fenofibrate does not affect CBF at the ischemic core (Inoue et al, 2003; Deplanque et al, 2003), the influence of fenofibrate on CBF in the ischemic penumbra is unknown. Moreover, the effect of fenofibrate on regional CBF (rCBF) under nonischemic conditions has not been examined. The influence on CBF could confound the interpretation of the attenuation by fenofibrate in inflammation or oxidative stress in the ischemic brain.

In this study, we measured the effects of fenofibrate on CBF in nonischemic mice and in ischemic mice that were subjected to middle cerebral artery occlusion (MCAO) and reperfusion. In addition, we examined the role of PPARα in the fenofibrate-induced increase in CBF in ischemic brain as fenofibrate failed to attenuate infarct size in PPARα-null mice after MCAO (Inoue et al, 2003; Deplanque et al, 2003). Furthermore, to gain insight into the molecular mechanism of the protection by fenofibrate, we analyzed the impact of fenofibrate on gene expression levels of PPARs and endothelial nitric oxide synthase (eNOS), which is one of the major players in CBF regulation, in the aorta and brain microvessels. We here show evidence that fenofibrate improves CBF in the ischemic brain through a PPARα-mediated mechanism.

Materials and methods

Animals

Animal usage and all procedures were approved by the Morehouse School of Medicine Animal Care and Use Committee. Wild-type C57BL/6 and 129S6/SvEv mice (male, 6-weeks old) were purchased from Charles River Laboratories (Wilmington, MA, USA) and Taconic (Germantown, NY, USA), respectively. Homozygous PPARα-null mice (129/Sv and C57BL/6 background) with a targeted mutation in PPARα putative ligand-binding domain (Lee et al, 1995) were purchased from Jackson Laboratory (Bar Harbor, ME, USA) and our PPARα-null mouse colony was maintained by breeding homozygous males and females. Their fur coat color is agouti with white belly and they appear normal in behavior. Altered responses to peroxisome proliferators in peroxisome proliferation and hepatocarcinogenesis have been reported (Lee et al, 1995). In addition, inflammation induced by leukotriene B4 or arachidonic acid is prolonged in this mouse strain (Gonzalez, 1997). Animals had free access to water and normal diet, and were maintained under a regular day/night cycle.

Fenofibrate Treatment

Animals were treated for 7 days with fenofibrate (0, 30, or 100 mg/kg) by oral administration through a feeding needle. As vehicle, 0.5% carboxymethyl cellulose (5 mL/kg) was used. Animals were randomly assigned to the treatment groups.

Middle Cerebral Artery Occlusion

For the study on infarct size, the type of treatment was masked from the two surgeons who performed MCAO. For laser speckle imaging, MCAO was performed by a surgeon who was aware of the treatment group. One hour after the final administration of fenofibrate, MCAO was induced. Animals were anesthetized, throughout the MCAO procedure and for 30 mins after reperfusion, with 1.5% isofluorane in a gas mixture of 70% N2O and 30% O2 using a vaporizer. Rectal temperature was maintained at 37°C with a thermostat-controlled heating pad. Animals were placed in the supine position and MCAO was induced on the left side with an 8-0 nylon monofilament coated with silicone resin and hardener mixture (Heraeus, Hanau, Germany) as described earlier (Steele et al, 2008). The common carotid artery and external carotid artery were ligated with a 5-0 silk suture. A miniclip (Ohwatsusho, Tokyo, Japan) was temporally applied to the left internal carotid artery. Then, the filament was introduced into the internal carotid artery through the external carotid artery, and advanced until the tip occluded the anterior cerebral artery with confirming CBF drop by using laser speckle imaging. For reperfusion, the filament was withdrawn and the common carotid artery was re-opened; however, the external carotid artery remained permanently ligated. In the infarct size study, CBF at ischemic core was monitored by laser Doppler flowmetry using a flexible fiber glass probe (FLO-C1, Omegawave, Tokyo, Japan).

Laser Speckle Blood Flow Imaging

Changes in cerebral surface blood flow were monitored by using a laser speckle blood flow imaging system (Omegazone, Omegawave). Animals were placed in the prone position and the skull was exposed by a midline scalp incision. The skull surface was diffusely illuminated by 780 nm laser light. The scattered light was filtered and detected by a CCD camera positioned above the head. The filter detected only scattered light that had a perpendicular polarization to the incident laser light. Raw speckle images were recorded by using a video capture card and Ultra Edit 2 software. The raw speckle images were used to compute speckle contrast, which corresponds to the number and velocity of moving red blood cells, that is CBF. Signal processing was performed by the algorithm developed by Forrester et al (2002). Color-coded blood flow images were obtained in high-resolution mode (638 pixels × 480 pixels; 1 image/sec). One blood flow image was generated by averaging numbers obtained from 20 consecutive raw speckle images. Cortical area in which CBF was either 20%, 30%, or 40% of the basal value was determined with a computerized image analysis system (MCID, Imaging Research, Cambridge, UK).

Cerebral Blood Flow [14C]Iodoantipyrine Autography

rCBF in nonischemic C57BL/6 mice was measured using quantitative autoradiography with [14C]iodoantipyrine according to Jay et al (1988) with modifications (Yamada et al, 2000). The femoral artery and vein were cannulated with a polyethylene catheter (PE-10, Becton Dickinson, Sparks, MD, USA) for continuous arterial blood pressure and heart rate monitoring and for drug infusion. Animals were under 1.5% isoflurane anesthesia with spontaneous respiration. Rectal temperature was maintained at 37°C. Arterial blood samples (50 μL) were collected through the catheter and pH and blood gases were analyzed. After achieving a stable blood pressure with pO2 and pCO2 within normal range, 14C-iodoantipyrine (5 μCi in 0.1 mL saline) was infused into the left femoral vein at progressively increasing rates over 1 min using a programmable pump. During this procedure, arterial blood samples were collected every 5 secs onto preweighed filter paper disks. One minute after starting infusion, animals were decapitated, and brains were quickly frozen with 2-methylbutane chilled on dry ice at −45°C. The blood-loaded filter paper disks were treated with Scintigest (Fisher Scientific, Pittsburgh, PA, USA) overnight and the radioactivity in blood samples was measured by liquid scintillation spectrometry 2 days later. For determination of tissue 14C concentration, 20 μm thick coronal brain sections were made using a cryostat, mounted on glass slides, and apposed to Kodak BioMax autoradiographic film (GE Healthcare, Arlington Heights, IL, USA) together with 14C standards (GE Healthcare). The density of the autoradiograms was measured with the MCID image analyzer. The software converts the optical density to radioactive content and to CBF using the radioactive standards and the 14C-iodoantipyrine blood concentration curve. In each treatment group, the mean rCBF value and standard deviation (s.d.) were calculated for each brain structure.

Infarct Size Measurement

In 129/Sv mice subjected to 60 mins of MCAO, infarct volume was determined at 24 h after reperfusion. Brains were fixed with 10% formalin and subsequently treated with phosphate-buffered saline (PBS) containing 20% sucrose. The brains were cut into 40 μm thick coronal sections with a freezing microtome. Sections from five levels with 2 mm intervals were stained with cresyl violet and infarct area was measured in a treatment type-masked manner by using the MCID imaging system.

Mouse Brain Microvessel Isolation

Mouse brain capillaries were isolated as reported earlier (Ospina et al, 2002) with minor modifications (Guo et al, 2009). Collected fresh brains were homogenized in ice-cold PBS (pH 7.4) with a loosely fitting Dounce homogenizer, and centrifuged at 2,000g for 5 mins at 4°C. The supernatant was removed and stored on ice. The pellet was re-suspended in PBS and centrifuged at 2,000g for 5 mins at 4°C. The supernatant was combined with the first supernatant and centrifuged at 3,000g for 10 mins at 4°C. The resulting pellet containing the parenchymal fraction was stored at −80°C. The pellet that was obtained after the second 2,000g centrifugation was re-suspended in PBS, carefully layered over a 15% dextran density gradient (molecular weight 35,000 to 40,000 kDa, Sigma Aldrich, St Louis, MO, USA), and centrifuged in a swinging-bucket rotor at 3,500g for 35 mins at 4°C. The supernatant was discarded, and the pellet was re-suspended in PBS, layered over dextran again and centrifuged at 3,500g for additional 35 mins. The resulting pellet was thoroughly washed with ice-cold PBS over a 70 μm nylon mesh and the collected cerebral vessels were stored at −80°C.

RNA Isolation and Real-Time PCR

RNA was isolated with Trizol (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. The PCR amplifications were performed in a 50 μL reaction volume containing 2 μL cDNA, 25 μL of iQ SYBR Green Supermix (Bio-Rad, Hercules, CA, USA), primer, and nuclease-free water. Primer sequences for the studied genes were as the follows: eNOS, forward, 5′-gaccctcaccgctacaacat-3′ and reverse, 5′-ctggccttctgctcattttc-3′ PPARα, forward, 5′-gcagctcgtacaggtcatca-3′ and reverse, 5′-ctcttcatccccaagcgtag-3′ PPARγ, forward, 5′-ttttcaagggtgccagtttc-3′ and reverse, 5′-aatccttggccctctgagat-3′ PPARβ, forward, 5′-tggagctcgatgacagtgac-3′ and reverse, 5′-gtactggctgtcagggtggt-3′ GAPDH, forward, 5′-aactttggcattgtggaagg-3′ and reverse, 5′-acacattgggggtaggaaca-3′. The PCR was performed in an iCycler iQ at 50°C for 2 mins, 95°C for 10 mins, followed by 35 cycles of 95°C for 10 secs, 55°C for 10 secs, and 72°C for 10 secs. The relative gene expression of eNOS and PPARs were calculated using the comparative Ct (cross-threshold) method. Briefly, the Ct of the housekeeping gene GAPDH was subtracted from the Ct of each target molecule to get ΔCt. The ΔCt value of control group sample was then subtracted from the ΔCt of the treatments to get the ΔΔCt value. Fold differences compared with control group sample are obtained by calculating 2−ΔΔCt for each treatment group.

Total Cholesterol and Triglyceride Measurement

Total cholesterol and triglyceride levels were, respectively, measured by using the Wako Cholesterol E assay kit and Wako L-Type TG M assay kit (Wako Diagnostics, Richmond, VA, USA) according to the manufacturer's instructions.

Statistical Analyses

Data are presented as mean±s.d. Statistical analyses were made using SPSS 15 software (SPSS, Chicago, IL, USA). One-way analysis of variance (ANOVA) followed by Scheffe post hoc analysis was used for autoradiography, arterial blood pressure, arterial blood gas analysis, and real-time PCR. Two-way repeated measures ANOVA followed by Scheffe post hoc analysis was performed for hemispheric CBF in wild-type mice, and Kruskal–Wallis followed by Mann–Whitney U-test was performed for ischemic areal size in C57BL/6 and infarct volume in 129/Sv. Unpaired Student's t-test was performed for hemispheric CBF and ischemic areal size in PPARα-null mice. P<0.05 was considered statistically significant.

Results

Fenofibrate Improves CBF in Ischemic Cortex in Wild-Type Mice

Laser speckle imaging through the intact skull showed CBF reductions in the left hemisphere after MCAO in C57BL/6 mice (Figure 1A). We examined the temporal changes of cortical CBF in the ischemic hemisphere in the absence and presence of fenofibrate. In the vehicle-treated animals, the cortical CBF in the ischemic hemisphere continued to decrease up to 2 h after MCAO, suggesting expansion of ischemic area (Figure 1B). However, the fenofibrate-treated animals did not show a continued reduction in CBF (Figure 1B), indicating that fenofibrate limited the progression of impaired CBF. The difference, compared with vehicle, was greater with longer occlusion periods and was significant at 2 h after MCAO at both 30 and 100 mg/kg doses.

Figure 1
Effects of fenofibrate on CBF after filamentous middle cerebral artery occlusion (MCAO). (A) Color-coded laser speckle image taken from a representative animal at 5 mins after MCAO. Both hemispheres are shown. Note that the green vertical signal ...

To obtain topographical information, the cortical surface area, in which rCBF was less than 20%, 30%, or 40% of the basal value, was determined in each animal. Figure 1C shows a representative case from the vehicle-treated group at 2 h after MCAO. As the occlusion time was prolonged, the area with rCBF deficit expanded in the vehicle-treated animals (Figure 1D). Fenofibrate-treated animals showed a significantly smaller area in which rCBF was less than 20% of the basal level after 2 h of MCAO (Figure 1E), suggesting that fenofibrate attenuated the expansion of ischemic core area. Similarly the area in which rCBF was less than 30% was significantly smaller in the fenofibrate-treated groups.

After reperfusion following 2 h of MCAO, fenofibrate (30 mg/kg)-treated group exhibited an improved restoration of rCBF toward the basal level compared with the vehicle group (Figure 1B). At 30 mins after reperfusion, the area in which rCBF was less than 20%, 30%, or 40% was significantly reduced by fenofibrate (30 mg/kg) compared with vehicle (Figure 1F). The higher dose (100 mg/kg) did not affect such areal sizes.

Fenofibrate Does not Affect CBF in Nonischemic Animals

To measure the basal level of rCBF in nonischemic C57BL/6 animals, we performed quantitative autoradiography with the [14C]iodoantipyrine method. Mean rCBF values in each brain area were compared among the three treatment groups. There was no significant difference in mean values in the analyzed brain structures (Table 1). In addition, there was no significant difference in arterial blood pressure measurement and arterial blood analysis (Table 2).

Table 1
Effects of fenofibrate on regional cerebral blood flow (rCBF) in nonischemic mice
Table 2
Effects of fenofibrate on physiological parameters in mice

The current treatment protocols with fenofibrate did not affect cholesterol and triglyceride levels in young male C57BL/6 mice on normal diet (Table 3), suggesting that the CBF improvement by fenofibrate in the ischemic brain was not related with the lipid lowering effect of fenofibrate.

Table 3
Effects of fenofibrate on total cholesterol and trigryceride levels in nonischemic mice

Fenofibrate Does not Improve rCBF in PPARα-Null Mice

We investigated whether PPARα is required for the fenofibrate-induced increase of CBF in ischemic brain. PPARα-null mice were treated for 7 days with either vehicle or fenofibrate (30 mg/kg). This dose was effective in wild-type animals. There was no difference between fenofibrate and vehicle in cortical CBF in PPARα-null animals during MCAO and after reperfusion (Figure 2A). No difference was detected between the two groups in the cortical surface areal size, in which CBF was less than 20%, 30%, or 40% at 2 h after MCAO (Figure 2B), suggesting the possibility that the improvement by fenofibrate in rCBF is related with PPARα.

Figure 2
Fenofibrate does not affect CBF in PPARα-null mice after MCAO. (A) Graph showing %CBF in the ischemic hemisphere. Error bars, s.d. (B) Graph showing areal size in which CBF is below 20%, 20% to 30%, and 30% ...

Fenofibrate Attenuates Infarct Volume in Wild-Type Mice

To confirm brain tissue protection, we analyzed the impact of fenofibrate (30 mg/kg) on infarct volume in 129/Sv mice subjected to 60 mins of MCAO. A total of 20 animals were randomly assigned to either vehicle (n=10) or fenofibrate treatment (n=10) for 7 days. One animal in the fenofibrate group died because of technical problem during MCAO. Three animals in each group did not survive the reperfusion period. There was no difference in neurological score at 24 h after reperfusion (Figure 3A). Fenofibrate significantly attenuated infarct volume at 24 h after reperfusion: vehicle, 23.7%±5.0% contralateral hemisphere (n=7); fenofibrate, 16.9%±5.4% contralateral hemisphere (n=6) (Figure 3B). Fenofibrate did not affect CBF at the ischemic core measured by laser Doppler flowmetry (Table 4).

Figure 3
Effects of fenofibrate on stroke outcome in 129/Sv wild-type mice after 60 mins of MCAO. (A) Graph showing neurological score measured by a modified Bederson score at 24 h after reperfusion; 0, normal; 1, decreased forepaw extension; 2, ...
Table 4
Effects of fenofibrate on %CBF at ischemic core in 129/Sv mice

Effects of Fenofibrate on Gene Expression Levels of PPARs and eNOS

To analyze the impact of fenofibrate on PPAR expression, we measured mRNA levels of PPARs in brain and aorta in nonischemic animals that were treated with fenofibrate for 7 days. Fenofibrate significantly increased only PPARα in the aorta (Figure 4A) and isolated brain microvessels (Figure 4B). Fenofibrate showed a small increase in PPARγ in brain microvessels, but this increase was not statistically significant (P[gt-or-equal, slanted]0.05 by ANOVA) (Figure 4B). Conversely, the brain fraction containing neurons and glia showed decreases in PPARα and PPARγ; however, PPARβ was not affected (Figure 4C). We next measured the effects of fenofibrate on eNOS level as eNOS has been shown to mediate CBF increases by statins, another type of lipid lowering drug (Endres et al, 1998). Fenofibrate did not significantly alter eNOS mRNA levels in both of the aorta and brain microvessels (Figure 4D).

Figure 4
Effects of fenofibrate on mRNA levels of PPARs (A to C) and eNOS (D) in aorta, brain microvessels (BMVC) fraction, and neuro-glial fraction in nonischemic mice. Mice on normal diet were treated with fenofibrate for 7 days. mRNA levels were determined ...

Discussion

In this study, laser speckle imaging documented both areal and temporal changes in cortical surface CBF in the same animal as reported by other investigators (Dunn et al, 2001; Zhou et al, 2008). We observed a progressive expansion of surface area in which CBF was severely compromised (<30%) at least up to 2 h after MCAO in vehicle-treated animals (Figure 1D). In addition, even after 30 mins of reperfusion, there was a substantial area with poor perfusion (Figure 1F), supporting no-reflow phenomenon (Hossmann, 1983; del Zoppo and Mabuchi, 2003). Fenofibrate improved CBF in the ischemic brain during MCAO (Figure 1E). In addition, fenofibrate (30 mg/kg) enhanced CBF recovery after reperfusion (Figure 1F), suggesting that fenofibrate reduced the no-reflow phenomenon. This study also confirmed an attenuation in infarct size by fenofibrate in 129/Sv mice subjected to 60 mins of MCAO. Therefore, the infarct size reduction by fenofibrate was likely attributable to the CBF improvement in the ischemic brain, at least in part.

The mechanism by which PPARα activation by fenofibrate exerts the cerebrovascular protective effects remains unknown. Deplanque et al (2003) showed that fenofibrate increased acetylcholine-induced endothelium-dependent relaxation of isolated middle cerebral artery from rats. Thus, PPARα activation may also enhance cerebral artery relaxation in the ischemic brain. In addition, antiinflammatory action of PPARα activation may prevent white blood cells or platelet adhesion/aggregation to microvessels in the ischemic area (Yamakawa et al, 1987; Kataoka et al, 2004), by doing so fenofibrate may improve CBF in the ischemic brain. Consistent with this notion, prevention of adhesion molecule expression by fenofibrate has been shown in ischemic brain (Deplanque et al, 2003). As part of such an investigation, we measured the influence of fenofibrate on eNOS mRNA levels in the brain microvessles. The effect was not significant. Conversely, the mRNA levels of eNOS in the aorta tended to decrease (Figure 4D). These findings contrast with those reported for statins, another type of lipid lowering drug, which has been shown to improve CBF by eNOS-mediated mechanisms (Endres et al, 1998). Clarifying the mechanistic linkage between PPARα activation and CBF improvement in the ischemic brain may provide insights into a novel intervention to enhance neuronal survivability after ischemic stroke.

CBF-independent mechanisms may also contribute to the fenofibrate-induced attenuation in infarct size. Our recent study with another type of PPARα agonist gemfibrozil suggested CBF-independent neuroprotection against ischemia (Guo et al, 2009). Deplanque et al (2003) showed that chronic treatment with fenofibrate increased major antioxidant enzymes including copper/zinc superoxide dismutase in the nonischemic mouse brain, which is likely to contribute to the neuroprotection in the brain after ischemia. Compared with the antiinflammatory action of PPARα agonists applied to microglia (Jana et al, 2007), the consequence of their direct action on neurons is less clear. Santos et al (2005) showed that a selective PPARα agonist Wy-14643 (100 μmol/L) increased survivability of rat hippocampal dissociated neurons subjected to β-amyloid peptide. Contrary, Bento-Abreu et al (2007) observed that Wy-14643 (>50 μmol/L) was neurotoxic. We recently found that a higher dose of gemfibrozil (120 mg/kg) tended to aggravate brain swelling after permanent MCAO (Guo et al, 2009). The neurotoxicity of PPARα agonists at their high concentrations might cause the loss of effect by fenofibrate at 100 mg/kg on the CBF after reperfusion (Figure 1F). Developing a novel PPARα agonist with minimal neurotoxicity will help to further improve stroke outcome by PPARα activation.

The beneficial effect by fenofibrate was not seen in PPARα-null mice (Figure 2). In addition, we found that mRNA levels of PPARα were significantly increased by fenofibrate in the brain microvessels and aorta (Figures 4A and 4B). Thus, PPARα was likely a mediator of the cerebrovascular protective effects of fenofibrate. The selective effects of fenofibrate on the mRNA levels of PPARα in the aorta and brain microvessels may be related with its higher affinity as a ligand for PPARα over PPARγ and PPARβ. Our recent study with another fibrate gemfibrozil showed similar findings in the aorta. However, gemfibrozil increased not only PPARα but also PPARγ and PPARβ to a lesser extent (Guo et al, 2009), which may also reflect the binding ability of gemfibrozil to PPARγ and PPARβ. In addition, the increase in mRNA levels of PPARα by both fenofibrate and gemfobrozil may suggest a positive feedback loop as a regulatory mechanism of PPARα gene expression.

Gemfibrozil has been shown to decrease PPARβ in both brain microvessels and neuroglial fractions (Guo et al, 2009); however, fenofibrate did not significantly reduce PPARβ in this study (Figures 4B and 4C). As exacerbated infarct formation after permanent focal cerebral ischemia has been shown in PPARβ-null mice (Arsenijevic et al, 2006; Pialat et al, 2007), the lack of reduction in PPARβ expression levels in the fenofibrate-treated brains may explain the more prominent infarct reduction by fenofibrate compared with that by gemfibrozil (Inoue et al, 2003; Guo et al, 2009). In contrast, both PPARα and PPARγ were reduced by fenofibrate in the neuroglial fraction. These findings suggest that gene expression of PPAR is regulated in an organ-dependent manner. The findings also raise the possibility that the decrease in PPARα and PPARγ by fenofibrate in the neuroglial fraction might counteract the beneficial effect of fenofibrate against ischemic stroke, as selective neuronal PPARγ gene disruption has been shown to increase susceptibility to brain damage after MCAO (Zhao et al, 2009), and because magnetic resonance imaging showed increased infarct volume in PPARα-null mice compared with their wild-type controls (Pialat et al, 2007).

In summary, we showed that pretreatment with fenofibrate improved the penumbral CBF during MCAO. In addition, fenofibrate enhanced CBF recovery after reperfusion. These effects by fenofibrate required PPARα. The mechanism by which fenofibrate exerts cerebrovascular protection needs to be determined. As gemfibrozil has been show to reduce the incidence of stroke in patients (Bloomfield Rubins et al, 2001), further investigation of the impact of prophylactic usage of fibrates on stroke outcome may be meritorious.

Acknowledgments

Supported in part by NS034194, NS048532, and NS060659 from NIH/NINDS and S21MD000101 from NIH/NCMHHD. The study was conducted in a facility constructed with support from Research Facilities Improvement Grant 1 C06 RR-07571 from NIH/NCRR. We thank Dr Zhihong Huang at Johnson and Johnson Pharmaceutical Research and Development and Dr Christian Waeber at Massachusetts General Hospital for their advice on the iodoantipyrine autoradiography method. We thank Drs Peter R MacLeish and Benveniste Morris at Morehouse School of Medicine for critical reading and comments.

Footnotes

Conflict of interest

The authors declare no conflict of interest.

References

  • Arsenijevic D, de Bilbao F, Plamondon J, Paradis E, Vallet P, Richard D, Langhans W, Giannakopoulos P. Increased infarct size and lack of hyperphagic response after focal cerebral ischemia in peroxisome proliferator-activated receptor beta-deficient mice. J Cereb Blood Flow Metab. 2006;26:433–445. [PubMed]
  • Bento-Abreu A, Tabernero A, Medina JM. Peroxisome proliferator-activated receptor-alpha is required for the neurotrophic effect of oleic acid in neurons. J Neurochem. 2007;103:871–881. [PubMed]
  • Bloomfield Rubins H, Davenport J, Babikia V, Brass LM, Collins D, Wexler L, Wagner S, Papademetriou V, Rutan G, Robins SJ, VA-HIT Study Group Reduction in stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol: The Veterans Affairs HDL Intervention Trial (VA-HIT) Circulation. 2001;103:2828–2833. [PubMed]
  • Bordet R, Ouk T, Petrault O, Gele P, Gautier S, Laprais M, Deplanque D, Duriez P, Staels B, Fruchart JC, Bastide M. PPAR: a new pharmacological target for neuroprotection in stroke and neurodegenerative diseases. Biochem Soc Trans. 2006;34:1341–1346. [PubMed]
  • Chinetti G, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflamm Res. 2000;49:497–505. [PubMed]
  • Cunard R, DiCampli D, Archer DC, Stevenson JL, Ricote M, Glass CK, Kelly CJ. WY14,643, a PPARα ligand, has profound effects on immune responses in vivo. J Immunol. 2002;169:6806–6812. [PubMed]
  • Cuzzocrea S, Di Paola R, Mazzon E, Genovese T, Muià C, Caputi AP. WY 14643, a potent exogenous PPAR-alpha ligand, reduces intestinal injury associated with splanchnic artery occlusion shock. Shock. 2004;22:340–346. [PubMed]
  • del Zoppo GJ, Mabuchi T. Cerebral microvessel responses to focal ischemia. J Cereb Blood Flow Metab. 2003;23:879–894. [PubMed]
  • Deplanque D, Gele P, Petrault O, Six I, Furman C, Bouly M, Nion S, Dupuis B, Leys D, Fruchart JC, Cecchelli R, Staels B, Duriez P, Bordet R. Peroxisome proliferator-activated receptor-alpha activation asa mechanism of preventive neuroprotection induced by chronicfenofibrate treatment. J Neurosci. 2003;23:6264–6271. [PubMed]
  • Dreyer C, Keller H, Mahfoudi A, Laudet V, Krey G, Wahli W. Positive regulation of the peroxisomal beta-oxidation pathway by fatty acids through activation of peroxisome proliferator-activated receptors (PPAR) Biol Cell. 1993;77:67–76. [PubMed]
  • Dunn AK, Bolay H, Moskowitz MA, Boas DA. Dynamic imaging of cerebral blood flow using laser speckle. J Cereb Blood Flow Metab. 2001;21:195–201. [PubMed]
  • Endres M, Laufs U, Huang Z, Nakamura T, Huang P, Moskowitz MA, Liao JK. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci USA. 1998;95:8880–8885. [PubMed]
  • Escher P, Wahli W. Peroxiome proliferator-activated receptors: insight into multiple cellular functions. Mutat Res. 2000;448:121–138. [PubMed]
  • Forrester KR, Stewart C, Tulip J, Leonard C, Bray RC. Comparison of laser speckle and laser Doppler perfusion imaging: measurement in human skin and rabbit articular tissue. Med Biol Eng Comput. 2002;40:687–697. [PubMed]
  • Gibson GG. Peroxisome proliferators: paradigms and prospects. Toxicol Lett. 1993;68:193–201. [PubMed]
  • Gonzalez FJ. Recent update on the PPAR alpha-null mouse. Biochimie. 1997;79:139–144. [PubMed]
  • Green S, Wahli W. Peroxisome proliferator-activated receptors: finding the orphan a home. Mol Cell Endocrinol. 1994;100:149–153. [PubMed]
  • Guo Q, Wang G, Liu X, Namura S. Effects of gemfibrozil on outcome after permanent middle cerebral artery occlusion in mice. Brain Res. 2009;1279:121–130. [PMC free article] [PubMed]
  • Hossmann KA. Neuronal survival and revival during and after cerebral ischemia. Am J Emerg Med. 1983;1:191–197. [PubMed]
  • Inoue H, Jiang XF, Katayama T, Osada S, Umesono K, Namura S. Brain protection by resveratrol and fenofibrate against stroke requires peroxisome proliferator-activated receptor alpha in mice. Neurosci Lett. 2003;352:203–206. [PubMed]
  • Jana M, Jana A, Liu X, Ghosh S, Pahan K. Involvement of phosphatidylinositol 3-kinase-mediated up-regulation of I kappa B alpha in anti-inflammatory effect of gemfibrozil in microglia. J Immunol. 2007;179:4142–4152. [PMC free article] [PubMed]
  • Jay TM, Lucignani G, Crane AM, Jehle J, Sokoloff L. Measurement of local cerebral blood flow with [14C]iodoantipyrine in the mouse. J Cereb Blood Flow Metab. 1988;8:121–129. [PubMed]
  • Kataoka H, Kim SW, Plesnila N. Leukocyte-endothelium interactions during permanent focal cerebral ischemia in mice. J Cereb Blood Flow Metab. 2004;24:668–676. [PubMed]
  • Lee SS-T, Pineau T, Drago J, Lee EJ, Owens JW, Kroetz DL, Fernandez-Salguero PM, Westphal H, Gonzalez FJ. Targeted disruption of the α isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Mol Cell Biol. 1995;15:3012–3022. [PMC free article] [PubMed]
  • Lovett-Racke AE, Hussain RZ, Northrop S, Choy J, Rocchini A, Matthes L, Chavis JA, Diab A, Drew PD, Racke MK. Peroxisome proliferator-activated receptor alpha agonists astherapy for autoimmune disease. J Immunol. 2004;172:5790–5798. [PubMed]
  • Ospina JA, Krause DN, Duckles SP. 17beta-estradiol increases rat cerebrovascular prostacyclin synthesis by elevating cyclooxygenase-1 and prostacyclin synthase. Stroke. 2002;33:600–605. [PubMed]
  • Pialat JB, Cho TH, Beuf O, Joye E, Moucharrafie S, Langlois JB, Nemoz C, Janier M, Berthezene Y, Nighoghossian N, Desvergne B, Wiart M. MRI monitoring of focal cerebral ischemia in peroxisome proliferator-activated receptor (PPAR)-deficient mice. NMR Biomed. 2007;20:335–342. [PubMed]
  • Santos MJ, Quintanilla RA, Toro A, Grandy R, Dinamarca MC, Godoy JA, Inestrosa NC. Peroxisomal proliferation protects from beta-amyloid neurodegeneration. J Biol Chem. 2005;280:41057–41068. [PubMed]
  • Sivarajah A, Chatterjee PK, Hattori Y, Brown PA, Stewart KN, Todorovic Z, Mota-Filipe H, Thiemermann C. Agonists of peroxisome-proliferator activated receptor-alpha (clofibrate and WY14643) reduce renal ischemia/reperfusion injury in the rat. Med Sci Monit. 2002;8:BR532–BR539. [PubMed]
  • Staels B, Koenig W, Habib A, Merval R, Lebret M, Torra IP, Delerive P, Fadel A, Chinetti G, Fruchart JC, Najib J, Maclouf J, Tedgui A. Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. Nature. 1998;393:790–793. [PubMed]
  • Steele EC, Jr, Guo Q, Namura S. Filamentous middle cerebral artery occlusion causes ischemic damage to the retina in mice. Stroke. 2008;39:2099–2104. [PubMed]
  • Von Knethen AA, Brune B. Delayed activation of PPARgamma by LPS and IFN-gamma attenuates the oxidative burst in macrophages. FASEB J. 2001;15:535–544. [PubMed]
  • Wayman NS, Hattori Y, McDonald MC, Mota-Filipe H, Cuzzocrea S, Pisano B, Chatterjee PK, Thiemermann C. Ligands of the peroxisome proliferator-activated receptors (PPAR-gamma and PPAR-alpha) reduce myocardial infarct size. FASEB J. 2002;16:1027–1040. [PubMed]
  • Yamada M, Huang Z, Dalkara T, Endres M, Laufs U, Waeber C, Huang PL, Liao JK, Moskowitz MA. Endothelial nitric oxide synthase-dependent cerebral blood flow augmentation by L-arginine after chronic statin treatment. J Cereb Blood Flow Metab. 2000;20:709–717. [PubMed]
  • Yamakawa T, Yamaguchi S, Niimi H, Sugiyama I. White blood cell plugging and blood flow maldistribution in the capillary network of cat cerebral cortex in acute hemorrhagic hypotension: an intravital microscopic study. Circ Shock. 1987;22:323–332. [PubMed]
  • Yue TL, Bao W, Jucker BM, Gu JL, Romanic AM, Brown PJ, Cui J, Thudium DT, Boyce R, Burns-Kurtis CL, Mirabile RC, Aravindhan K, Ohlstein EH. Activation of peroxisome proliferator-activated receptor-alpha protects the heart from ischemia/reperfusion injury. Circulation. 2003;108:2393–2399. [PubMed]
  • Zhao X, Strong R, Zhang J, Sun G, Tsien JZ, Cui Z, Grotta JC, Aronowski J. Neuronal PPARgamma deficiency increases susceptibility to brain damage after cerebral ischemia. J Neurosci. 2009;29:6186–6195. [PMC free article] [PubMed]
  • Zhou C, Shimazu T, Durduran T, Luckl J, Kimberg DY, Yu G, Chen XH, Detre JA, Yodh AG, Greenberg JH. Acute functional recovery of cerebral blood flow after forebrain ischemia in rat. J Cereb Blood Flow Metab. 2008;28:1275–1284. [PMC free article] [PubMed]

Articles from Journal of Cerebral Blood Flow & Metabolism are provided here courtesy of SAGE Publications